Figure 2
From: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Panobinostat decreases TNBC cell proliferation and viability. Cells from four TNBC cell lines (MDA-MB-157, MDA-MB-231, MDA-MB-468, BT549) and three ER-positive cell lines (MCF-7, MDA-MB-361, ZR-75) were treated with panobinostat (50, 100, 200 nM) or vehicle (DMSO) for 24 hours and assayed by (A) MTT proliferation and (B) trypan blue exclusion assays. Data are represented as percent control (mean ± SEM) of three independent experiments, (**, P < 0.01; ***, P < 0.001). DMSO, dimethyl sulfoxide; ER, estrogen receptor; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; SEM, standard error of the mean; TNBC, triple-negative breast cancer.